Potential as new standard treatment of HER2+ metastatic breast cancer
The results of the DESTINY-Breast03 study was presented at Presidential symposium, ESMO 2021 by Javier Cortés, MD, head of International Breast Cancer Center in Barcelona. DESTINY-Breast03 study are a multicenter, open-label, randomized phase 3 study comparing the efficacy and safety of trastuzumab deruxtecan vs trastuzumab emtansine for patients with HER2+ metastatic breast cancer. According to Javier Cortés This study will lead to a paradigm shift in the treatment of HER2+ metastatic breast cancer, because trastuzumab deruxtecan have the potential to be the new standard treatment for this group.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.